GU Cancers 2023 | CARINA: cabozantinib post first-line immune-oncology CPI-containing combination in aRCC

Anand Sharma, MD, D.Phil, MRCP, MBBS, Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Northwood, UK, outlines the retrospective CARINA (NCT04957160) trial assessing cabozantinib post first-line immune-oncology checkpoint inhibitor containing combination in patients with advanced renal cell carcinoma with an aim to understand where cabozantinib is administered are first-line containing combination therapy. Primary outcome measures include description of the treatment sequence pathway from first-line to second-line and description of the treatment sequence pathway from first-line up to the second-line for cabozantinib. Secondary outcome measures include overall-survival (OS), time to treatment discontinuation, physician defined breast response by line, overall response rate (ORR) and duration of treatment by line. 281 patients were enrolled onto the trial. Median PFS was approximately 44 weeks, the ORR was 22 weeks and the OS 66 months. Overall, these results were better than other therapies used in the second-line for patients with advanced renal cell carcinoma. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.